

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated Tuesday, August 10, 2021 (the “**Prospectus**”) of Shanghai HeartCare Medical Technology Corporation Limited 上海心瑋醫療科技股份有限公司 (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an invitation to induce an offer or an offer to sell, acquire, purchase or subscribe for securities of the Company. Potential investors should read the Prospectus carefully for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in Hong Kong, the United States or elsewhere. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”). The Offer Shares may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States. The Offer Shares may be offered, sold or delivered (i) solely to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act and (ii) outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.



Shanghai HeartCare Medical Technology Corporation Limited

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

STABILIZATION ACTIONS, END OF STABILIZATION PERIOD AND LAPSE OF OVER-ALLOTMENT OPTION

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on September 12, 2021, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

Further information of the stabilizing actions undertaken by Goldman Sachs (Asia) L.L.C. as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it during the stabilization period is set out in this announcement.

LAPSE OF OVER-ALLOTMENT OPTION

Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited (for themselves and on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on September 12, 2021.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

Pursuant to Section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), the Company announces that the stabilization period in connection with the Global Offering ended on September 12, 2021, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The stabilizing actions undertaken by the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period are set out below:

- (1) over-allocations of an aggregate of 990,250 H Shares in the International Offering, representing approximately 15% of the Offer Shares initially offered under the Global Offering before any exercise of the Over-allotment Option; and
- (2) the purchases of an aggregate of 990,250 H Shares at a price in the range of HK\$119.00 to HK\$147.40 per H Share (exclusive of brokerage of 1.0%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period, representing approximately 15% of the Offer Shares initially offered under the Global Offering before any exercise of the Over-allotment Option, to be delivered to certain cornerstone investors who have agreed to a delayed delivery of H Shares subscribed by them under the relevant cornerstone investment agreements they entered into. The last purchase made by the Stabilizing Manager on the market during the stabilization period was on September 10, 2021 at the price of HK\$143.00 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

LAPSE OF OVER-ALLOTMENT OPTION

Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited (for themselves and on behalf of the International Underwriters) did not exercise the Over-allotment Option during the stabilization period and the Over-allotment Option lapsed on September 12, 2021.

PUBLIC FLOAT

The Directors confirm that the Company continues and will continue to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules whereby at least 25% of the Company's total number of issued H Shares must at all times be held by the public.

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
Mr. Wang Guohui
Chairman

Hong Kong, September 12, 2021

As at the date of this announcement, the Board comprises Mr. WANG Guohui as Chairman and executive Director, Ms. ZHANG Kun as an executive Director, Mr. DING Kui, Mr. LIU Yanbin, Mr. CHEN Gang, Mr. OUYANG Xiangyu as non-executive Directors, and Mr. GUO Shaomu, Mr. FENG Xiangqian and Mr. GONG Ping as independent non-executive Directors.